Abstract:Background: Vascular calcification has a global health impact that is closely linked to bone loss. The Receptor Activator of Nuclear Factor Kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system, fundamental for bone metabolism, also plays an important role in vascular calcification. The Leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4), a novel receptor for RANKL, regulates bone remodeling, and it appears to be involved in vascular calcification. Besides RANKL, LGR4 interacts with R-spondins (RSPOs), which are known for their roles in bone but are less understood in vascular calcification. Methods: Studies were conducted in rats with chronic renal failure fed normal or high phosphorus diets for 18 weeks, with and without control of circulating parathormone (PTH) levels, resulting in different degrees of aortic calcification. Additionally, vascular smooth muscle cells (VSMCs) were cultured under non-calcifying (1 mM phosphate) and calcifying (3 mM phosphate) media with different concentrations of PTH. To explore the role of RANKL in VSMC calcification, increasing concentrations of soluble RANKL were added to non-calcifying and calcifying media. The effects mediated by RANKL binding to its receptor LGR4 were investigated by silencing the LGR4 receptor in VSMCs. Furthermore, the gene expression of the RANK/RANKL/OPG system and the ligands of LGR4 was assessed in human epigastric arteries obtained from kidney transplant recipients with calcification scores (Kauppila Index). Results: Increased aortic calcium in rats coincided with elevated systolic blood pressure, upregulated Lgr4 and Rankl gene expression, downregulated Opg gene expression, and higher serum RANKL/OPG ratio without changes in Rspos gene expression. Elevated phosphate in vitro increased calcium content and expression of Rankl and Lgr4 while reducing Opg. Elevated PTH in the presence of high phosphate exacerbated the increase in calcium content. No changes in Rspos were observed under the conditions employed. The addition of soluble RANKL to VSMCs induced genotypic differentiation and calcification, partly prevented by LGR4 silencing. In the epigastric arteries of individuals presenting vascular calcification, the gene expression of RANKL was higher. Conclusions: while RSPOs show minimal impact on VSMC calcification, RANKL, interacting with LGR4, drives osteogenic differentiation in VSMCs, unveiling a novel mechanism beyond RANKL-RANK binding.

Vasorin as an actor of bone turnover?

Vasorin-deficient mice display disturbed vitamin D and mineral homeostasis in combination with a low bone mass phenotype

Expression of Vaspin in the Joint and the Levels in the Serum and Synovial Fluid of Patients with Osteoarthritis.

The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis

The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics

RANKL, but Not R-Spondins, Is Involved in Vascular Smooth Muscle Cell Calcification through LGR4 Interaction

Vaspin Deficiency Failed to Promote the Proliferation of BMSCs in Osteoarthritis

Osteoporosis Influences Osteogenic but Not Angiogenic Response During Bone Defect Healing in a Rat Model

Vaspin promotes chondrogenic differentiation of BMSCs via Akt activation in osteoarthritis

Vaspin attenuates the apoptosis of human osteoblasts through ERK signaling pathway

A Novel Long-Term ex vivo Model for Studying Vascular Calcification Pathogenesis: The Rat Isolated-Perfused Aorta

Specialized post-arterial capillaries facilitate adult bone remodelling

Deposition of collagen type I onto skeletal endothelium reveals a new role for blood vessels in regulating bone morphology

Sphingosine-1-Phosphate (S1P) promotes osteogenesis by stimulating osteoblast growth and neovascularization in a vascular endothelial growth factor (VEGF)-dependent manner

Role of NFATc1 in the Bone-Vascular Axis Calcification Paradox

Sclerostin is Involved in Osteogenic Transdifferentiation of Vascular Smooth Muscle Cells in Chronic Kidney Disease-Associated Vascular Calcification with Non-Canonical Wnt Signaling.

Vascular Calcification: New Insights Into BMP Type I Receptor A

Modeling In Vitro Osteoarthritis Phenotypes in a Vascularized Bone Model Based on a Bone-Marrow Derived Mesenchymal Cell Line and Endothelial Cells

Single-Cell Integration of BMD GWAS Results Prioritize Candidate Genes Influencing Age-Related Bone Loss

Sclerostin Protects Against Vascular Calcification Development in Mice

Vasostatins: new molecular targets for atherosclerosis, post-ischemic angiogenesis and arteriogenesis